NEUP Stock Analysis: Buy, Sell, or Hold?
NEUP - Neuphoria Therapeutics Inc. Common Stock
$5.03
0.26 (5.45%)
▲
5d:
+10.07%
30d:
+14.32%
90d:
+22.38%
BUY
MODERATE Confidence
Analysis Updated: Apr 20, 2026 12:00 AM ET
Earnings: May 19, 2026
27d
Get Alerted When NEUP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NEUP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NEUP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NEUP is currently trading at $5.03, which is considered extended relative to its 30-day fair value range of $4.26 to $4.76.
Technical Outlook: Technically, NEUP is in a uptrend. The price is approaching resistance at $4.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.5% recently.
Market Sentiment: NEUP has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.77 (+94.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NEUP is in a uptrend. The price is approaching resistance at $4.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.5% recently.
Market Sentiment: NEUP has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.77 (+94.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$4.26 -
$4.76
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+5.7% above fair value)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.5%)
- BULLISH: Trading 94.2% below Wall St target ($9.77)
Fair Price Analysis
30-Day Fair Range
$4.26 -
$4.76
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$4.25
Resistance Level
$4.80
Current Trend
Uptrend
Technical data as of
Apr 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.31
Wall Street Target
$9.77
(+94.2%)
Profit Margin
-37.8%
Share & Embed Analysis
Last updated: April 21, 2026 3:30 AM ET
Data refreshes hourly during market hours. Next update: 4:30 AM
Data refreshes hourly during market hours. Next update: 4:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NEUP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$93 | 61 BUY |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$125 | 59 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$134 | 59 HOLD |
